Product logins

Find logins to all Clarivate products below.


Anne Lecocq

Senior Vice President and General Manager, Research & Development

Anne Lecocq is a seasoned life sciences executive with over 20 years of experience. She began her career in the pharmaceutical and generics industries, specializing in regulatory compliance and chemistry, manufacturing and controls (CMC), before joining Clarivate in 2008.

At Clarivate, Anne has held multiple leadership roles overseeing data and content strategy for Cortellis solutions spanning drug discovery, clinical trials, competitive intelligence, safety, and regulatory intelligence. In her current role as General Manager of the R&D Business, she drives product innovation and strategic growth for the Cortellis product suite, enabling biopharma organizations to accelerate the delivery of life-changing therapies to patients through actionable intelligence and advanced analytics.

Anne holds dual master’s degrees in Biotechnology & Chemistry and Regulatory Affairs. Based in Paris, France, she is passionate about leveraging her multidisciplinary expertise to advance global R&D efficiency through transformative intelligence.

Latest news

News June 17, 2026
Clarivate Releases Journal Citation Reports 2026

Advancing transparency and responsible journal evaluation London, U.K. June 17 2026 — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the release of the Journal…

Partner news June 16, 2026
U.S. News Unveils 2026-2027 Best Global Universities Rankings

Universities in more than 100 countries are evaluated in the newest edition. Washington, D.C. – June 16, 2026 – U.S. News & World Report, the global authority in education rankings…

Partner news
News June 15, 2026
Clarivate’s IPfolio Selected by Mitsubishi Fuso

Managing intellectual property more efficiently with leading data and expertise London, U.K. June 15, 2026. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that Mitsubishi…

Related resources

Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization